Cited by 411Endometrial and Cervical Cancer TreatmentsBreast Cancer Treatment StudiesOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

Clinical actionability of molecular targets in endometrial cancer

Open access

Urick, Mary Ellen, Bell, Daphne W.·2019·Nature Reviews Cancer

DOI 10.1038/s41568-019-0177-xPMC PMC7446243

Open this paper in CoChat — free account

Abstract

Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women's health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41568-019-0177-x

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
EMT: 2016
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Yang, W., Lum, A. M., Senz, J., Boyd, N., Pike, J. A., Anglesio, M. S., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 1,007
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S. C. Y., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 989
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Stelloo, E., Nout, R. A., Osse, E. M., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 856
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan, V. W., Yang, H., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y., Wolk, A., Wentzensen, N., Weiss, N. S., Webb, P. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.2596 · Cited by 830
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Milestones of Lynch syndrome: 1895–2015
Lynch, H. T., Snyder, C., Shaw, T. G., Heinen, C. D., & Hitchins, M. P. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3878 · Cited by 808
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Massard, C., Michiels, S., Ferté, C., Deley, M. L., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E. E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 802
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
Kommoss, S., McConechy, M. K., Kommoss, F. K. F., Leung, S. C. Y., Bunz, A.-K., Magrill, J., Britton, H. M., Kommoss, F. K. F., Grevenkamp, F., Karnezis, A. N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 791
International patterns and trends in endometrial cancer incidence, 1978-2013.
Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx214 · Cited by 760
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S. J., Stover, E. H., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 695
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 642
Cancer-associated mutations in endometriosis without cancer
Anglesio, M. S., Papadopoulos, N., Ayhan, A., Nazeran, T. M., Noë, M., Horlings, H. M., Lum, A., Jones, S., Senz, J., Seckin, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614814 · Cited by 628
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Berger, A. C., Korkut, A., Kanchi, R. S., Hegde, A. M., Lenoir, W. F., Liu, W., Liu, Y., Fan, H., Shen, H., Ravikumar, V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.014 · Cited by 621
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A. M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 538
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Fader, A. N., Roque, D. M., Siegel, E. R., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L. J., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 521
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Ott, P. A., Bang, Y., Berton-Rigaud, D., Élez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I. J., Mehnert, J. M., Aung, K. L., Lopez, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 512
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative.
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke‐Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 483
Indexed Pain Journals
(U.S.), N. L. O. M. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 474
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 467
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458
Integrated Molecular Characterization of Uterine Carcinosarcoma
Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.010 · Cited by 440
Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.2820 · Cited by 426
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
Gallo, M. L., O’Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O’Neil, N. J., Price, J. C., Zhang, S., England, B. M., Godwin, A. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 426
Self-citation
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424
Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium
Suda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Tamura, R., Mori, Y., Yamawaki, K., Adachi, S., Takahashi, T., Kase, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.037 · Cited by 414
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, J., Hirshfield, K. M., Damare, S., Lane, K., Sokol, L. O., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 376
Cancer of the corpus uteri
Amant, F. C., Mirza, M. R., Koskas, M., & Creutzberg, C. L. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12612 · Cited by 357
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
Schwaederle, M. C., Zhao, M. M., Lee, J. J., Lazar, V., Leyland-Jones, B. R., Schilsky, R. L., Mendelsohn, J. M., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 349
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
Tashiro, H., Isacson, C., Levine, R. L., Kurman, R. J., Cho, K. R., & Hedrick, L. (1997) · Europe PMC (PubMed Central) · Cited by 345
p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
Sherman, M. E., Bur, M. E., & Kurman, R. J. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90204-x · Cited by 342
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D. N., Stelloo, E., Nout, R. A., Valtcheva, N., Depreeuw, J., ter Haar, N. T., Noske, A., Amant, F. C., Tomlinson, I. P. M., Wild, P. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju402 · Cited by 337
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Kurnit, K. C., Kim, G. N., Fellman, B. M., Urbauer, D. L., Mills, G. B., Zhang, W., & Broaddus, R. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.15 · Cited by 325
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Zhao, S., Choi, M., Overton, J. D., Bellone, S., Roque, D. M., Cocco, E., Guzzo, F., English, D. P.-G., Varughese, J., Gasparrini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222577110 · Cited by 323
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 323
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists
Soslow, R. A., Tornos, C. S., Park, K. J., Malpica, A. L., Matías‐Guiu, X., Oliva, E., Parkash, V., Carlson, J. W., McCluggage, W. G., & Gilks, C. B. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000518 · Cited by 317
Cancer of the corpus uteri
Amant, F. C., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 311
Minimal functional driver gene heterogeneity among untreated metastases
Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Heyde, A., Attiyeh, M. A., Kohutek, Z. A., Tokheim, C. J., Brown, A., DeBlasio, R. M., Niyazov, J., et al. (2018) · Science · doi:10.1126/science.aat7171 · Cited by 310
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 308
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
Clarke, M. A., Devesa, S. S., Harvey, S. V., & Wentzensen, N. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00151 · Cited by 301
PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.
Levine, R. L., Cargile, C. B., Blazes, M. S., van Rees, B. P., Kurman, R. J., & Ellenson, L. H. (1998) · PubMed · Cited by 290
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
McConechy, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L., Wiegand, K. C., McAlpine, J. N., Shah, S. P., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.107 · Cited by 287
Factors associated with Type I and Type II endometrial cancer
Felix, A. S., Weissfeld, J. L., Stone, R. A., Bowser, R. P., Chivukula, M., Edwards, R. P., & Linkov, F. Y. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9612-8 · Cited by 285
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
for the PORTEC Study Group, Wortman, B. G., Creutzberg, C. L., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Mens, J. W., Slot, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0310-8 · Cited by 284
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N. C., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes‐Pereira, A. M., Natrajan, R., Lambros, M. B. K., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A. G., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 254
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers
Wang, Y., Li, L., Douville, C. B., Cohen, J. D., Yen, T., Kinde, I., Sundfelt, K., Kjær, S. K., Hruban, R. H., Shih, I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8793 · Cited by 251
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses
Kuhn, E., Wu, R., Guan, B., Wu, G., Zhang, J., Wang, Y., Song, L., Yuan, X., Wei, L., Roden, R. B. S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs345 · Cited by 249
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Jankú, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D. D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 241
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 236
Self-citation
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
Zhao, S., Bellone, S., Lopez, S., Thakral, D., Schwab, C. L., English, D. P.-G., Black, J., Cocco, E., Choi, J., Zammataro, L. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614120113 · Cited by 232
The genetic landscape of endometrial clear cell carcinomas
DeLair, D. F., Burke, K. A., Selenica, P., Lim, R. S., Scott, S. N., Middha, S., Mohanty, A. S., Cheng, D. T., Berger, M. F., Soslow, R. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4947 · Cited by 230
Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice
Daikoku, T., Hirota, Y., Tranguch, S. L., Joshi, A. R., DeMayo, F. J., Lydon, J. P., Ellenson, L. H., & Dey, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1274 · Cited by 224
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Rudd, M. L., Price, J. C., Fogoros, S. K., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0540 · Cited by 222
Self-citation
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Hussein, Y. R., Weigelt, B., Levine, D. A., Schoolmeester, J. K., Dao, L. N., Balzer, B. L., Liles, G. B., Karlan, B. Y., Köbel, M., Lee, C., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.143 · Cited by 220
Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Brinton, L. A., Felix, A. S., McMeekin, D. S., Creasman, W. T., Sherman, M. E., Mutch, D. G., Cohn, D. E., Walker, J. L., Moore, R. G., Downs, L. S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.02.023 · Cited by 216
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
McMeekin, D. S., Tritchler, D., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8722 · Cited by 215
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
Gibson, W. J., Høivik, E. A., Halle, M. K., Taylor-Weiner, A. N., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 211
New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care
Talhouk, A., & McAlpine, J. N. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0035-4 · Cited by 208
Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type
Zighelboim, I., Goodfellow, P. J., Gao, F., Gibb, R. K., Powell, M. A., Rader, J. S., & Mutch, D. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2107 · Cited by 202
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E. S., Alva, A. S., Janeway, K. A., Stella, P. J., Voest, E. E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 199
Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada, H., Enomoto, T., Fujita, M., Yoshino, K., Nakashima, R., Kurachi, H., Haba, T., Wakasa, K., Shroyer, K. R., Tsujimoto, M., et al. (1997) · PubMed · Cited by 193
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
McConechy, M. K., Talhouk, A., Leung, S. C. Y., Chiu, D. S., Yang, W., Senz, J., Reha-Krantz, L. J., Lee, C., Huntsman, D. D., Gilks, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2233 · Cited by 192
PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
Oda, K., Okada, J., Timmerman, L., Rodriguez‐Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
Jardim, D. L. F., Schwaederle, M. C., Wei, C., Lee, J. J., Hong, D. S., Eggermont, A., Schilsky, R. L., Mendelsohn, J. M., Lazar, V., & Kurzrock, R. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv253 · Cited by 187
FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
Byron, S. A., Gartside, M. G., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 187
POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium
Meng, B., Hoang, L. N., McIntyre, J. B., Duggan, M. A., Nelson, G. S., Lee, C., & Köbel, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.006 · Cited by 182
Polymerase ɛ ( POLE ) mutations in endometrial cancer: Clinical outcomes and implications for L ynch syndrome testing
Billingsley, C. C., Cohn, D. E., Mutch, D. G., Stephens, J. A., Suarez, A. A., & Goodfellow, P. J. (2014) · Cancer · doi:10.1002/cncr.29046 · Cited by 174
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
Jones, S., Stransky, N., McCord, C. L., Cerami, E. G., Lagowski, J. P., Kelly, D. D., Angiuoli, S. V., Sausen, M., Kann, L. M., Shukla, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6006 · Cited by 169
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
Wortman, B. G., Bosse, T., Nout, R. A., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Westerveld, H. G., van den Berg, H., Slot, A., Winter, K. A. J. D., Verhoeven-Adema, K. W., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.020 · Cited by 169
Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Talhouk, A., Derocher, H., Schmidt, P., Leung, S. C. Y., Milne, K., Gilks, C. B., Anglesio, M. S., Nelson, B. H., & McAlpine, J. N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3241 · Cited by 162
A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group.
Gruber, S., & Thompson, W. D. (1996) · PubMed · Cited by 153
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States
Freedman, A. N., Klabunde, C. N., Wiant, K. F., Enewold, L., Gray, S. W., Filipski, K. K., Keating, N. L., Leonard, D. G. B., Lively, T., McNeel, T. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00169 · Cited by 153
Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
Sherman, M. E., Sturgeon, S. R., Brinton, L. A., Potischman, N. A., Kurman, R. J., Berman, M. L., Mortel, R., Twiggs, L. B., Barrett, R. J., & Wilbanks, G. D. (1997) · PubMed · Cited by 152
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Lieb, S., Blaha-Ostermann, S., Kamper, E., Rippka, J., Schwarz, C., Ehrenhöfer-Wölfer, K., Schlattl, A., Wernitznig, A., Lipp, J., Nagasaka, K., et al. (2019) · eLife · doi:10.7554/elife.43333 · Cited by 151
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Soumerai, T. E., Donoghue, M. T. A., Bandlamudi, C., Srinivasan, P., Chang, M. T., Zamarin, D., Cadoo, K. A., Grisham, R. N., O'Cearbhaill, R. E., Tew, W. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0412 · Cited by 144
Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability
Kategaya, L., Perumal, S. K., Hager, J. H., & Belmont, L. D. (2019) · iScience · doi:10.1016/j.isci.2019.02.006 · Cited by 144
Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis
Jin, Z., Ogata, S., Tamura, G., Katayama, Y., Fukase, M., 矢島, 美., & Motoyama, T. (2003) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000092134.88121.56 · Cited by 136
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Eggink, F. A., van Gool, I. C., Leary, A. F., Pollock, P. M., Crosbie, E. J., Mileshkin, L., Jordanova, E. S., Adam, J., Freeman-Mills, L., Church, D. N., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1264565 · Cited by 132
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S., & Amant, F. C. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1537-8 · Cited by 127
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Cosgrove, C. M., Cohn, D. E., Hampel, H., Frankel, W. L., Jones, D. M., McElroy, J. P., Suarez, A. A., Zhao, W., Chen, W., Salani, R., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.003 · Cited by 126
Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations
Ngeow, J. Y. Y., Stanuch, K., Mester, J. L., Barnholtz‐Sloan, J. S., & Eng, C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6656 · Cited by 125
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Bian, X., Gao, J., Luo, F., Rui, C., Zheng, T., Wang, D., Wang, Y., Roberts, T. M., Liu, P., Zhao, J. J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.326 · Cited by 124
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124
Methylated DNA collected by tampons: a new tool to detect endometrial cancer.
Fiegl, H., Gattringer, C., Widschwendter, A., Schneitter, A., Ramoni, A., Sarlay, D., Gaugg, I., Goebel, G., Müller, H. M., Mueller-Holzner, E., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.882.13.5 · Cited by 123
Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
Britton, H. M., Huang, L., Lum, A. M., Leung, S. C. Y., Shum, K., Kale, M., Burleigh, A., Senz, J., Yang, W., McConechy, M. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.098 · Cited by 115
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
Maritschnegg, E., Wang, Y., Pecha, N., Horvat, R., Nieuwenhuysen, E. V., Vergote, I. B., Heitz, F., Sehouli, J., Kinde, I., Diaz, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3083 · Cited by 114
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., Famuyide, A. O., Clayton, A. C., Halling, K. C., Kerr, S. E., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.01.552 · Cited by 107
In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas
McConechy, M. K., Hoang, L. N., Chui, M. H., Senz, J., Yang, W., Rozenberg, N., Mackenzie, R., McAlpine, J. N., Huntsman, D. D., Clarke, B. A., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.18 · Cited by 104
Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes
Yang, H., Wentzensen, N., Trabert, B. L., Gierach, G. L., Felix, A. S., Gunter, M. J., Hollenbeck, A. R., Park, Y., Sherman, M. E., & Brinton, L. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws200 · Cited by 102
Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study
Nair, N., Camacho‐Vanegas, O., Rykunov, D., Dashkoff, M., Camacho, S. C., Schumacher, C. A., Irish, J. C., Harkins, T. T., Freeman, E., Garcia, I., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002206 · Cited by 102
Targeted mutation analysis of endometrial clear cell carcinoma
Hoang, L. N., McConechy, M. K., Meng, B., McIntyre, J. B., Ewanowich, C. A., Gilks, C. B., Huntsman, D. D., Köbel, M., & Lee, C. (2014) · Histopathology · doi:10.1111/his.12581 · Cited by 97
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression
Ashley, C. W., Paula, A. D. C., Kumar, R., Mandelker, D. L., Pei, X., Riaz, N., Reis-Filho, J. S., & Weigelt, B. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.032 · Cited by 94
Molecular characterization of uterine clear cell carcinoma
An, H., Logani, S., Isacson, C., & Ellenson, L. H. (2004) · Modern Pathology · doi:10.1038/modpathol.3800057 · Cited by 94
High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
Stelloo, E., Nout, R. A., Naves, L. C. L. M., ter Haar, N. T., Creutzberg, C. L., Smit, V. T. H. B. M., & Bosse, T. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.012 · Cited by 90
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone, S., Bignotti, E., Lonardi, S., Ferrari, F., Centritto, F., Masserdotti, A., Pettinella, F., Black, J., Menderes, G., Altwerger, G. H., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.023 · Cited by 84
Synthetically lethal nanoparticles for treatment of endometrial cancer
Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 82
ARID1A Is Essential for Endometrial Function during Early Pregnancy
Kim, T. H., Yoo, J., Wang, Z., Lydon, J. P., Khatri, S., Hawkins, S. M., Leach, R. E., Fazleabas, A. T., Young, S. L., Lessey, B. A., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005537 · Cited by 79
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients
Bellone, S., Centritto, F., Black, J., Schwab, C. L., English, D. P.-G., Cocco, E., Lopez, S., Bonazzoli, E., Predolini, F., Ferrari, F., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.027 · Cited by 76
Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Kuhn, E., Bahadirli-Talbott, A., & Shih, I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.209 · Cited by 75
Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing
Gallo, M. L., Rudd, M. L., Urick, M. E., Hansen, N. F., Zhang, S., Program, N. C. S., Lozy, F., Sgroi, D. C., Vidal, A., Matías‐Guiu, X., et al. (2017) · Cancer · doi:10.1002/cncr.30745 · Cited by 75
Self-citation
Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
van Gool, I. C., Rayner, E., Osse, E. M., Nout, R. A., Creutzberg, C. L., Tomlinson, I. P. M., Church, D. N., Smit, V. T. H. B. M., de Wind, N., Bosse, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0266 · Cited by 74
DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice
Wang, H., Douglas, W., Lia, M., Edelmann, W., Kucherlapati, R., Podsypanina, K., Parsons, R. E., & Ellenson, L. H. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62573-4 · Cited by 69
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
Wild, P. J., Ikenberg, K., Fuchs, T. J., Rechsteiner, M., Georgiev, S., Fankhauser, N., Noske, A., Roessle, M., Caduff, R. F., Dellas, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101063 · Cited by 66
Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040.
Gaber, C., Meza, R., Ruterbusch, J. J., & Cote, M. L. (2017) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-016-0292-2 · Cited by 66
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Miyasaka, A., Oda, K., Ikeda, Y., Wada‐Hiraike, O., Kashiyama, T., Enomoto, A., Hosoya, N., Koso, T., Fukuda, T., Inaba, K., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-179 · Cited by 65
Expression profiles of carcinosarcoma of the uterine corpus—are these similar to carcinoma or sarcoma?
Chiyoda, T., Tsuda, H., Tanaka, H., Kataoka, F., Nomura, H., Nishimura, S., Takano, M., Susumu, N., Saya, H., & Aoki, D. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20947 · Cited by 65
Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 58
Endometrial Carcinomas With Clear Cells
Han, G., Soslow, R. A., Wethington, S. L., Levine, D. A., Bogomolniy, F., Clement, P. B., Köbel, M., Gilks, C. B., & DeLair, D. F. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000162 · Cited by 56
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Auguste, A., Genestie, C., de Bruyn, M., Adam, J., Formal, A. L., Drusch, F., Pautier, P., Crosbie, E. J., MacKay, H. J., Kitchener, H. C., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0055-1 · Cited by 56
Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia
Kipp, B. R., Medeiros, F., Campion, M. B., Distad, T. J., Peterson, L. M., Keeney, G. L., Halling, K. C., & Clayton, A. C. (2008) · Cancer · doi:10.1002/cncr.23636 · Cited by 56
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Meng, X., Bi, J., Li, Y., Yang, S., Zhang, Y., Li, M., Liu, H., Li, Y., McDonald, M. E., Thiel, K. W., et al. (2018) · Cancers · doi:10.3390/cancers10050149 · Cited by 53
Emergence, Involution, and Progression to Carcinoma of Mutant Clones in Normal Endometrial Tissues
Mutter, G. L., Monte, N. M., Neuberg, D. S., Ferenczy, A. S., & Eng, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0108 · Cited by 52
β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers
Myers, A. P., Barry, W. T., Hirsch, M. S., Matulonis, U. A., & Lee, L. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.010 · Cited by 51
Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers
Mota, A., Colás, E., García‐Sanz, P., Campoy, I., Rojo‐Sebastián, A., Gatius, S., García, Á., Chiva, L. M., Alonso, S., Gil‐Moreno, A., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.143 · Cited by 51
Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).
Fleming, G. F., Emens, L. A., Eder, J. P., Hamilton, E. P., Liu, J. F., Liu, B., Molinero, L. L., Fassò, M., O'Hear, C. E., & Braiteh, F. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5585 · Cited by 51
Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors
Ayhan, A., Mao, T., Rahmanto, Y. S., Zeppernick, F. A., Ogawa, H., Wu, R., Wang, T., & Shih, I. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.22 · Cited by 51
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Jeske, Y. W. A., Ali, S., Byron, S. A., Gao, F., Mannel, R. S., Ghebre, R. G., DiSilvestro, P., Lele, S., Pearl, M. L., Schmidt, A. P., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.031 · Cited by 50
Endometrial cancer—targeted therapies myth or reality? Review of current targeted treatments
Lheureux, S., & Oza, A. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.016 · Cited by 49
Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma
Russo, M., Broach, J. R., Sheldon, K. E., Houser, K. R., Liu, D. J., Kesterson, J. P., Phaëton, R., Hossler, C., Hempel, N., Baker, M. J., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.07.003 · Cited by 41
Endometrial brush biopsy for the diagnosis of endometrial cancer.
Priore, G. D., Williams, R., Harbatkin, C. B., Ls, W., Mittal, K., & Gc, Y. (2001) · PubMed · Cited by 40
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study
Chawla, A., Jankú, F., Wheler, J. J., Miller, V. A., Ryan, J., Anhorn, R., Zhou, Z., & Signorovitch, J. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00074 · Cited by 39
The NCI-MATCH trial and precision medicine in gynecologic cancers
Barroilhet, L. M., & Matulonis, U. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.008 · Cited by 39
Endocervical adenocarcinoma in situ: An analysis of cellular features
Biscotti, C. V., Gero, M. A., Toddy, S. M., Fischler, D. F., & Easley, K. A. (1997) · Diagnostic Cytopathology · doi:10.1002/(sici)1097-0339(199711)17:5 · Cited by 38
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
Meng, X., Laidler, L. L., Kosmacek, E. A., Yang, S., Xiong, Z., Zhu, D., Wang, X., Dai, D. D., Zhang, Y., Wang, X., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.004 · Cited by 36
Palbociclib has antitumour effects on Pten‐deficient endometrial neoplasias
Santamaría, M. D., Mirantes, C., Eritja, N., Felip, I., Navaridas, R., Gatius, S., Santacana, M., Colás, E., Moiola, C. P., Schoenenberger-Arnaiz, J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4896 · Cited by 35
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
Meng, X., Dizon, D. S., Yang, S., Wang, X., Zhu, D., Thiel, K. W., & Leslie, K. K. (2013) · Obstetrics and Gynecology International · doi:10.1155/2013/828165 · Cited by 30
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas
Gallo, M. L., Rudd, M. L., Urick, M. E., Hansen, N. F., Merino, M. J., Mutch, D. G., Goodfellow, P. J., Mullikin, J. C., & Bell, D. W. (2017) · Cancer · doi:10.1002/cncr.30971 · Cited by 29
Self-citation
Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors
Ta, R. M., Hecht, J. L., & Lin, D. I. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.012 · Cited by 29
Activated Mutant p110α Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion
Joshi, A. R., Miller, C. A., Baker, S. J., & Ellenson, L. H. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.12.019 · Cited by 28
Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities
Terakawa, J., Serna, V. A., Taketo, M. M., Daikoku, T., Suarez, A. A., & Kurita, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814506116 · Cited by 28
Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma
Soslow, R. A., Wethington, S. L., Cesari, M., Chiappetta, D., Olvera, N., Shia, J., & Levine, D. A. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318273591a · Cited by 27
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
Shukla, S. A., Howitt, B. E., Wu, C. J., & Konstantinopoulos, P. A. (2016) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2016.12.009 · Cited by 26
Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978–2014
Faber, M. T., Frederiksen, K., Jensen, A., Aarslev, P. B., & Kjær, S. K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.015 · Cited by 23
Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma
de la Vega, L. L., Samaha, M. C., Hu, K. M., Bick, N. R., Siddiqui, J., Hovelson, D. H., Liu, C., Carter, C. S., Cho, K. R., Sciallis, A. P., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1178 · Cited by 22
Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?
Wong, A., & Ngeow, J. Y. Y. (2015) · BioMed Research International · doi:10.1155/2015/219012 · Cited by 22
Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms
Lin, M., Burkholder, K. A., Viswanathan, A. N., Neuberg, D. S., & Mutter, G. L. (2009) · Cancer · doi:10.1002/cncr.24218 · Cited by 22
Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy.
Wu, H. H., Casto, B. D., & Elsheikh, T. M. (2003) · PubMed · Cited by 19
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI‐2 and dinaciclib
Urick, M. E., & Bell, D. W. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22867 · Cited by 15
Self-citation
Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice1
Wang, X., Khatri, S., Broaddus, R. R., Wang, Z., & Hawkins, S. M. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.133637 · Cited by 14
Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsyPreprint
Martignetti, J. A., Pandya, D. S., Nagarsheth, N. P., Chen, Y., Camacho, O., Tomita, S. A., Brodman, M. L., Ascher‐Walsh, C., Kolev, V., Cohen, S., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a003269 · Cited by 13
Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
Musselman, K., Glynn, S. M., Mosquera, J. M., Elemento, O., Sboner, A., Beltran, H., & Holcomb, K. (2019) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2019.01.013 · Cited by 8
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.
Rodon, J. A., Soria, J., Berger, R., Miller, W. H., Lazar, V., Rubin, E., Tsimberidou, A. M., Saintigny, P., Ackerstein, A., Braña, I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12011 · Cited by 8
Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping
Bergstrom, C. P., Geest, K. D., O’Gara, R., Corless, C. L., & Morgan, T. K. (2016) · Reproductive Sciences · doi:10.1177/1933719116648213 · Cited by 6
Adenomatous Polyposis Syndromes: Polymerase Proofreading-Associated Polyposis
Palles, C., Latchford, A. R., & Valle, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-74259-5_8 · Cited by 6
A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues
Kareem, B. N., Karlsen, F., Holm, R., Hennig, E. M., Suo, Z., Emilsen, E., Hellesylt, E., & Nesland, J. M. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199712)183:4 · Cited by 4
Untitled work
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4

Sorted by citations

The potential role of RNA N6-methyladenosine in Cancer progression
Wang, T., Kong, S., Tao, M., & Ju, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01204-7 · Cited by 1,044
Endometrial cancer
Makker, V., MacKay, H. J., Ray-Coquard, I. L., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 734
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases
Lu, Q., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., & Yang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01756-w · Cited by 391
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 204
Progesterone Actions and Resistance in Gynecological Disorders
MacLean, J. A., & Hayashi, K. (2022) · Cells · doi:10.3390/cells11040647 · Cited by 199

See all 411

Authors: Urick, M. E., & Bell, D. W.
Affiliations: National Institutes of Health (US)
Corresponding author: Bell, Daphne W.
ORCID: Urick, Mary Ellen
Bell, Daphne W.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2019-08-06
Volume: 19
Issue: 9
Pages: 510-521
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-019-0177-x
PMC: PMC7446243
OpenAlex: W2965204233
Cited by: 405
References: 157
Citations by year: 2026: 19 · 2025: 57 · 2024: 58 · 2023: 70 · 2022: 101 · 2021: 66 · 2020: 32 · 2019: 2
FWCI: 8.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 HG999999)
National Human Genome Research Institute (Z01HG200338, ZIAHG200379, ZIAHG200338)
Topics: Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: endometrial cancer, molecular subtyping, molecular targets, targeted therapy, early detection, risk stratification, endometrioid carcinoma, serous carcinoma, clear cell carcinoma, histological subtypes, prognosis
MeSH terms: Animals, Carcinoma, Female, Humans, Immunotherapy, Mutation, Prognosis, Risk, Sarcoma, Biomarkers, Tumor, Endometrial Neoplasms, Risk Assessment, Proteomics, Mice, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical actionability of molecular targets in endometrial cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks